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Background. Cerebral vasospasm is one of the leading courses for disability in aneurysmal subarachnoid hemorrhage. Effective
treatment of vasospasm is therefore one of the main priorities for these patients. We report about a case series of continuous
intra-arterial infusion of the calcium channel antagonist nimodipine for 1–5 days on the intensive care unit. Methods. In thirty
patients with aneurysmal subarachnoid hemorrhage and refractory vasospasm continuous infusion of nimodipine was started on
the neurosurgical intensive care unit. The effect of nimodipine on brain perfusion, cerebral blood flow, brain tissue oxygenation,
and blood flow velocity in cerebral arteries was monitored. Results. Based on Hunt & Hess grades on admission, 83% survived
in a good clinical condition and 23% recovered without an apparent neurological deficit. Persistent ischemic areas were seen in
100% of patients with GOS 1–3 and in 69% of GOS 4-5 patients. Regional cerebral blood flow and computed tomography perfusion
scanning showed adequate correlation with nimodipine application and angiographic vasospasm. Transcranial Doppler turned out
to be unreliable with interexaminer variance and failure of detecting vasospasm or missing the improvement. Conclusion. Local
continuous intra-arterial nimodipine treatment for refractory cerebral vasospasm after aSAH can be recommended as a low-risk
treatment in addition to established endovascular therapies.
1. Introduction
The incidence of aneurysmal subarachnoid hemorrhage is
located between 6 and 8 people out of every 100,000 each
year [1, 2]. 46% [1] to over 50% [3] of patients die within the
first two weeks of their aSAH. Medical care is not reached
by about 10–15% [4]. Complications such as neurogenic
pulmonary edema or neurogenic stunned myocardium kill
25% of the treated patients [5]. Vasospasm is one of the
main causes for prolonged neurologic deficit in patients
who reach either neurosurgical or endovascular treatment
for the aneurysm. 7% die of vasospasm and another 7%
develop severe neurologic deficit [6]. Treatment of vasospasm
is therefore one of the main priorities for these patients.
Mechanical endovascular interventions such as balloon
angioplasty or stenting are options for vasospasm of the great
vessels; however, the distally located smaller vessels cannot
be reached by the neuroradiologist and therefore need to
be treated with pharmacologic agents [7]. Amrinone [8], l-
arginine [9], colforsin daropate hydrochloride [10], papaver-
ine [11], verapamil [12], nicardipine [13], and nimodipine
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[14, 15] have been tested for their effect on vasospasm, but
none have shown significant difference to the others.
The pharmacological effect on the vessels is in some cases
limited to the period of infusion—either the procedure has to
be repeated [16] or the agent has to be applied continuously
for a few days until there is no more evidence of vasospasm
in neuromonitoring and angiography.
At our hospital all patients with aSAH are treated with
intravenous or oral nimodipine from the day of admission for
at least 21 days. Patients with detected vasospasm on angiog-
raphy receive intra-arterial nimodipine as a bolus application
in the angiography unit. Side effects as rapid increase in ICP,
thrombocytopenia, seizures, transient neurologic deficits
(mydriasis and brainstem depression), monocular blindness,
and paradoxical worsening of vasospasm as it is reported for
intra-arterial papaverine [16–19] were not seen.
We want to report our experience with continuous selec-
tive intra-arterial infusion of nimodipine via a catheter in the
internal carotid artery in refractory cerebral vasospasm.
2. Materials and Methods
2.1. Patient Population. From March 2006 until July 2013, 27
patients, who suffered aneurysmal subarachnoid hemorrhage
and developed cerebral vasospasm refractory to standard
hyperdynamic and endovascular therapy, were respectfully
treated with locally infused nimodipine via catheter in the
internal carotid artery for minimum of one day at the
neurosurgical intensive care unit at the Academic Teaching
Hospital of the Technical University of Munich, Klinikum
Munich-Bogenhausen. Two patients with clipped incidental
median cerebral artery (MCA)-aneurysms, who developed
refractory vasospasm seven and five days after the oper-
ation, were included as well. One patient was treated at
the interdisciplinary surgical intensive care unit at the aca-
demic teaching hospital of the LudwigMaximilianUniversity
Munich, Klinikum Munich-Schwabing. Data from 2006 to
September 2009 were analyzed retrospectively. During that
period of time, nine patients were treated by continuous
infusion of intra-arterial nimodipine. All patients, who were
treated from October 2009 to July 2013, were included in the
study prospectively. No patient was excluded. Randomization
was not performed.
2.2. Management of Subarachnoid Hemorrhage. In 26
patients, the aneurysm, causing the hemorrhage, was clipped.
There was one reclipping of a right-sided media aneurysm
located at the bifurcation. Vasospasm occurred nine days
after the second operation. In one case, there was only a
distal median cerebral artery (segment 1 (M1)-) aneurysm,
diagnosed in the computed tomography angiography, which
was clipped. After rebleeding, a digital subtraction angiog-
raphy was performed, showing a second aneurysm located at
the supraclinoidal internal carotid artery (ICA), which was-
coiled in the same session.TheMCA aneurysmwas shown to
be completely obstructed by the clip. We therefore proposed
that the ICA aneurysm had been ruptured initially. One
patient with a communicating artery aneurysm died before
treatment of the aneurysm. We recorded only two patients
who were exclusively treated by coiling.
Detection of vasospasm depended on the initial Hunt
& Hess grade. Patients grouped from H&H 0–2 usually
developed either a focal neurologic deficit, for example,
speech disturbance and hemiparesis, or loss of consciousness.
Those who were classified as Hunt & Hess 3 or higher on
admission were monitored with regional cerebral blood flow
(rCBF) with the Bowman system (Hemedex Inc., Cambridge,
MA, USA) and local tissue oxygenation with Licox probes
(Integra Neuroscience, Andover, UK). External ventricu-
lar drainages were placed in the right lateral ventricle to
measure intracranial pressure and drain cerebrospinal fluid
(CSF) when necessary. If Hunt & Hess 0–2 patients lost
consciousness due to vasospasm or other reason they were
monitored equally to the Hunt & Hess 3+ patients. When
angiography was performed prior to placing rCBF and ptiO2
probes, they were located in an area supplied by a vasospastic
vessel. Depending on CSF circulation an external ventricular
drainage or a parenchymal probe was placed.
Data were monitored by ICUpilot (CMA, Solna, Sweden)
with sampling frequency of 1/min. Depth of anesthesia
could be supervised with bispectral index (BIS) (Covidien
Healthcare).
Transcranial Doppler measurements were taken daily or
every second day.
2.3. Management of Vasospasm. After clipping or coiling
of the aneurysm systolic blood pressure was elevated to
150mmHg. When detecting vasospasm we started stan-
dard triple H therapy with hypertension, hypervolemia, and
hemodilution.
In cases of neurologic or neuromonitoring parameter
deterioration, a CAT scan in combination with perfusion
CT was performed to rule out causes other than vasospasm
and to detect areas of reduced or delayed cerebral perfusion
and blood flow or manifested ischemic areas marked as
infarctions already. The perfusion scan should represent
all territories of the three main cerebral arteries, namely,
the anterior, middle, and posterior cerebral artery, and is
therefore located at the upper basal ganglia as an axial slice.
Digital subtraction angiography was performed in gen-
eral anesthesia without exception. Every patient with vasos-
pasm was treated with a thirty-minute lasting intra-arterial
infusion of 10mL (=2mg) nimodipine via the catheter
in the internal carotid artery. If postinfusion angiography
showed complete recurrence of vasospasm the catheter was
taken out. When vasospasm persisted after short-time local
intraarterial nimodipine infusion, the catheter was left in
place and continuous intra-arterial nimodipine infusion was
started on the intensive care unit. During the period of
intra-arterial nimodipine application, all patients who had
lost consciousness before angiography were sedated and
mechanically ventilated during the period of intra-arterial
nimodipine application on the ICU. Patients, who suffered
from specific focal neurologic deficit without impairment of
consciousness, were awakened after initial angiography with
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Figure 1: DSA before and after nimodipine application at the angiography unit. Digital subtraction angiography of the left internal carotid
artery before (a) and after (b) nimodipine application in the angiography unit. It shows slight improvement of vasospasm after nimodipine
infusion. Intra-arterial infusion of the calcium channel antagonist was continued on the neurosurgical intensive care unit.
catheter placement in order to monitor either the paresis
or speech deficit. In cases of elevated intracranial pressure
(ICP), all standard conservative treatment options were
exhausted before surgery was performed. Three of our thirty
patients underwent decompressive hemicraniectomy. One
had developed infarction of the right cerebellar hemisphere
due to vasospasm of the posterior inferior cerebellar artery
(PICA) and therefore had to be craniectomied suboccipitally.
For angiography, four or five French introducer sheaths
with a microcatheter were used. Before administration of
nimodipine, digital subtraction angiography was performed
by contrast application into both internal carotid arteries.
After identification of vasospastic vessels (see Figure 1), 0.2–
0.4mg nimodipine (1-2mL nimodipine solution) was admin-
istered via the catheter in the right or left ICA, depending
on the side of leading vasospasm, as a bolus. A 30-minute
infusion containing 2mg nimodipine (10mL nimodipine
solution) was then administered. To visualize the effect
of nimodipine on the vessels, a further angiography was
performed. Patients where no vasospasm could be noticed on
the second angiography had their catheters removed. These
patients included in our study showed slight improvement of
vasospasm but not complete normalization of vessel diameter
and configuration. The catheter was fixed with the tip in the
extracranial internal carotid artery for further continuous
nimodipine infusion at the ICU. In our retrospective analyzed
patient data, four patients were treated with a 30-minute
infusion of 10mL (2mg) nimodipine every 8 hours for 2–
5 days. In five of our retrospective patient data and all of
the prospective treated patients, the protocol was changed
to an infusion rate of 5mL/h (1mg/h) applied continuously.
Via a second line, which was connected to the catheter with
the tip placed in the external iliac artery, 10.000 IU/24 h
of heparin was given to prevent clotting of the introducer
sheaths with the microcatheter and avoid thrombosis related
to the nimodipine catheter tip in the internal carotid artery.
Depending on the neuromonitoring parameters or, in
wake patients, their improvement of symptoms, intra-arterial
nimodipine infusionwas stopped after 1–5 days. Inmost cases
before catheter removal, another angiographic control was
performed to observe the therapeutic effect on the vessels in
correlation with clinical improvement. On the other hand,
to avoid missing persistent vasospasm, that requires further
treatment. Nevertheless, we missed the final angiography in
a few cases because of weekend or public holiday on the day
of catheter removal.
3. Results
3.1. Baseline Characteristics. Patient data are listed in Table 1.
Mean patient age was 49.77 ± 10.67 standard deviation (SD)
years. The youngest was a 27-year-old woman and the oldest
a 76-year-old man. Mean Hunt & Hess grade was 3.07 ± 1.41
with 27% of the patients being gradedHunt &Hess 2. Hunt &
Hess 3 was documented in 23% and 20% were Hunt & Hess 4
and 5 each.
Mean onset of continuous intra-arterial nimodipine
application was day 9.19 ± 3.31.
3.2. Treatment Results. Mean outcome of all patients was
GOS 3.27 ± 1.46. From 19 patients with Hunt & Hess grade
3 and higher four patients died (GOS 1), three were in
a persistent vegetative state (GOS 2), and six had severe
disability with dependence on support (GOS 3). One case
received GOS 4 with minor disability and five patients left
the hospital without apparent deficits (GOS 5). Persistent
ischemic areas were seen in 100% of patients with GOS 1–3
and in 69% of GOS 4-5 patients.
In four patients vasospasm was shown to be refractory to
local nimodipine administration. They died from vasospas-
tic induced major cerebral infarcts. Another patient died
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Table 1: Clinical patient and treatment data.
Case















1 54 f 3 4 A com A 9 4 1 Clipping
2 42 f 5 4 MCA l 10 5 1 Clipping
3 43 f 5 4 MCA r 9 4 1 Clipping
4 42 m 3 3 MCA l + ICA l 5 2 5 Clipping
5 53 f 4 4 MCA r 8 4 5 Clipping
6 56 m 2 2 A com A 9 3 2 Clipping
7 43 f 3 4 MCA l 13 3 3 Clipping
8 29 m 5 3 P com A r 7 3 1 Clipping
9 48 f 2 2 A com A 5 3 4 Clipping
10 52 m 5 4 MCA r 14 2 2 Clipping +reclipping
11 48 f 3 4 MCA r + ICA r 6 + 10 3 + 3 5 Clipping +coiling
12 76 m 2 2 A com A 9 4 1 \
13 50 f 5 4 MCA l 6 3 2 Clipping
14 56 f 2 3 A com A 8 3 4 Clipping
15 27 f 2 2 MCA l + carotid T l 7 3 5 Clipping
16 40 m 4 4 A com A 8 + 12 3 + 3 4 Clipping
17 68 f 2 2 ICA l 10 3 3 Clipping
18 55 f 4 4 C1/C2 r 9 3 3 Clipping
19 62 f 2 3 A com A 6 2 5 Clipping
20 48 m 0 1 MCA r 7 3 3 Clipping
21 49 m 5 4 ICA r 11 3 3 Clipping
22 66 m 4 4 MCA r 12 2 3 Clipping
23 41 f 2 3 MCA l 10 5 4 Clipping
24 61 f 3 4 MCA r 1 + 10 3 + 3 3 Clipping
25 48 m 0 1 MCA l 5 2 5 Clipping
26 47 f 1 4 A com A 7 3 5 Coiling
27 42 f 3 3 MCA r 11 2 3 Clipping
28 38 m 3 4 P com A l 2 + 8 + 13 3 + 4 + 4 5 Coiling
29 53 f 4 4 A com A 12 3 2 Clipping
30 56 f 4 4 MCA r 20 1 5 Clipping
Case no.: case number; H & H grade: Hunt and Hess grade; treatm. ons. (day): first day of selective continuous intra-arterial nimodipine infusion; treatm.
dur. (days): duration of selective continuous intra-arterial nimodipine infusion in days; outcome (GOS): clinical outcome on discharge in Glasgow outcome
scale score; coiling versus clipping: interventional neuroradiologic aneurysm coiling versus microsurgical aneurysm clipping; f: female; m: male; r: right; l: left;
A com A: anterior communicating artery; MCA: median cerebral artery; ICA: internal carotid artery; P com A: posterior communicating artery; carotid T:
bifurcation of internal carotid artery; C1/C2: segments of the internal carotid artery; \: no coiling or clipping.
from other reason than vasospasm, which was angiograph-
ically cured. Overall results from continuous intra-arterial
nimodipine infusion were promising. 26 patients improved
from angiographically documented refractory vasospasm.
Anyway from the 25 survivors only 4 (16%) did not have
ischemic brain tissue areas at discharge. All of them reached
GOS 5. 17 (68%) patients showed minor cerebral infarcts,
which were inmultiple locations in 6 (24%) cases. Depending
on eloquence of the ischemic brain tissue, patients varied
betweenGOS 3 and 5. Patients havingmajor cerebral infarcts,
which occurred in 4 of the 25, left the hospital in a persistent
vegetative state (GOS 2).
After having finished the continuous intra-arterial nimo-
dipine therapy with resolved vasospasm on angiography, four
patients relapsed in having vasospasm and needed further
intra-arterial nimodipine treatment. One patient even had
to undergo three cycles before he recovered and ended up
without any neurologic deficit on discharge. The 56-year-
old female patient with a noted treatment onset on day
20 after bleeding had had two sessions of intra-arterial
nimodipine bolus applications at the angiography unit of
Klinikum Schwabing.
11 patients were graded Hunt & Hess equal or better than
2. One of those patients died of refractory cerebral vasospasm
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Table 2: rCBF before, at 2 and 6 hours, and 1–5 days after starting continuous selective intra-arterial nimodipine infusion, rCBF (mL/
100 g/min).
Case no. rCBF before rCBF at 2 hours rCBF at 6 hours rCBF day 1 rCBF day 2 rCBF day 3 rCBF day 4 rCBF day 5
1 14 22 24 23.3 17.6 9.5 6.3 0
2 17 61 66 44.7 34.8 24.3 7.3 4.2
3 17 46 48 47.3 45.8 36.3 37.5 0
4 16 61 63 50.1 44.4 0 0 0
5 19 58 54 45.6 38.3 33.7 35.1 0
6 12 38 34 33.1 28.4 19.0 0 0
7 13 46 46 43.8 36.2 33.4 0 0
8 12 49 44 23.0 19.3 12.5 0 0
9 17 47 50 48.7 43.9 38.3 0 0
10 16 23 25 22.3 14.5 0 0 0
11 16 73 68 53.8 49.7 45.7 0 0
12 14 24 20 23.7 22.6 12.2 9.3 0
13 12 40 33 30.4 24.0 22.2 0 0
16 15 53 54 45.3 39.3 37.2 0 0
18 8 57 50 38.4 30.6 20.4 0 0
21 12 46 44 29.6 22.9 17.5 0 0
22 7 40 39 35.2 33.8 0 0 0
23 15 55 51 44.8 41.6 37.9 33.9 35.6
24 16 60 54 46.2 42.9 26.7 0 0
27 14 43 44 36.2 22.3 0 0 0
28 12 45 43 36.7 36.8 39.4 0 0
29 9 24 34 23.0 15.7 13.5 0 0
rCBF: regional cerebral blood flow; 0: no continuous selective intra-arterial nimodipine application.
even before treatment of the aneurysm. Two had severe
disabilities and one is in a persistent vegetative state. Of the
five patients, who died during hospital stay, four developed
limiting infarctions due to refractory cerebral vasospasm and
one died of sepsis three days after ICA-catheter removal.
Microbiological tests found the catheter tip to be sterile. Since
the catheter is at least 50 cm in length and only the tipwas sent
away for tests, the result cannot be representative of the whole
catheter.
On CT angiography, we saw thrombotic vessel wall adhe-
sions within the extracranial common or internal carotid
artery in three patients. As all of these patients had cerebral
infarctions, an additional embolic insult cannot be excluded.
The ischemic areas anyway were all limited to territories of
vasospastic vessels.
Thirteen patients survived in a good clinical condition
(Glasgow outcome scale (GOS 4 and 5)). Five patients
classified as Hunt & Hess 3 and 4 on admission left the
hospital without apparent deficits (GOS 5).
Addressing the neuromonitoring modalities, we noticed
the greatest effects of intra-arterial nimodipine infusion to
rCBF parameters; see Table 2. ptiO2 values showed prompt
but lower alterations; see Table 3. Changes of intracranial
pressurewere no indicator for vasospasm. PerfusionCT scans
showed vasospasm related changes in 90% of our cases and
showed improvement correlating with angiographic results
and clinical symptoms; see Figure 2. Data from transcranial
Doppler were shown not to be reliable for exclusion or detec-
tion of vasospasm; see Table 4. For patient 1 improvement of
vasospasm is not shown and in patients 4 and 9 vasospasm
is not detected at all. Worsening of vasospasm is missed in
patients 25 and 30; only patient 10 showed adequate changes
in blood flow velocity.
We could not detect correlation between patient age and
duration of selective intra-arterial nimodipine application
(Spearman 𝑟 = −0.2290 (corrected for ties), 95% confidence
interval: −0.5522 to 0.1541, two-tailed 𝑃 value is 0.2236) or
outcome (Spearman 𝑟 = −0.1642 (corrected for ties), 95%
confidence interval: −0.5036 to 0.2192, two-tailed 𝑃 value is
0.3860, considered not significant). Results were the same for
correlation of sex and other parameters (Fisher’s exact test
and Spearman correlation test). Hunt & Hess did not predict
the duration of therapy (Spearman 𝑟 = 0.07569 (corrected
for ties), 95% confidence interval: −0.3028 to 0.4336, two-
tailed 𝑃 value is 0.6910), but the Spearman rank correlation
test showed significant difference in outcome (Spearman 𝑟 =
−0.4353 (corrected for ties), 95% confidence interval:−0.6936






Figure 2: Perfusion CT correlating with DSA. CT perfusion withMTT (sec) (a), TTP (sec) (b), CBF (mL/100 g/min) (c), and CBV (mL/100 g)
(d) showing circumscribed perfusion deficit on the territory of the leftMCA.No evidence of infarction as shown on native CT scan (f). Digital
subtraction angiography (e, g) of the left ICA from the same patient on the same day showing vasospasm of the left ICA above the ophthalmic
artery of the median and anterior cerebral artery.
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Table 3: ptiO2 before, 2 and 6 hours, and 1–5 days after starting continuous selective intra-arterial nimodipine infusion, ptiO2 (mmHg).
Case no. ptiO2 before ptiO2 at 2 hours ptiO2 at 6 hours ptiO2 day 1 ptiO2 day 2 ptiO2 day 3 ptiO2 day 4 ptiO2 day 5
1 9 21 20 15.4 10.9 4.3 3.7 0
2 4 20 19 19.2 19.4 14.3 4.8 2.9
3 14 22 23 19.3 21.5 22.3 22.4 0
4 14 27 26 23.4 23.5 0 0 0
5 15 29 26 26.3 26.8 24.2 27.9 0
6 9 18 17 17.5 18.3 12.2 0 0
7 11 14 16 16.3 17.2 17.5 0 0
8 6 15 16 14.2 9.3 4.2 0 0
9 12 19 22 22.3 24.8 24.7 0 0
10 10 18 17 17.9 18.0 0 0 0
11 14 22 25 23.4 22.9 22.6 0 0
12 5 16 17 14.3 14.9 7.9 6.6 0
13 8 20 22 23.6 22.8 22.0 0 0
16 13 21 24 22.4 21.8 22.9 0 0
18 5 18 19 21.1 18.3 18.6 0 0
21 11 20 19 19.3 20.4 18.3 0 0
22 8 18 18 19.5 17.3 0 0 0
23 10 23 22 24.7 24.4 28.7 30.5 29.3
24 14 20 22 20.3 12.3 9.8 0 0
27 14 21 21 22.3 19.5 0 0 0
28 14 25 24 24.3 24.0 25.6 0 0
29 7 17 16 16.9 18.3 16.2 0 0
ptiO2: partial tissue oxygenation; 0: no continuous selective intra-arterial nimodipine application.
Table 4: Transcranial Doppler mean flow values (cm/s) of the right- and left-sided median cerebral artery in six patients before and during
continuous intra-arterial nimodipine therapy.
Case no. Before i.a. nimodipine Day 1 Day 2 Day 3 Day 4
Right Left Right Left Right Left Right Left Right Left
1 184 156 190 183 174 199 168 186 193 205
4 115 94 110 114 89 74
9 83 87 75 73 70 81 92 80
10 204 220 164 156 128 140
25 98 110 95 112 92 98
30 90 86 73 71
to −0.07778, two-tailed 𝑃 value is 0.0162); see Figure 3.
The onset of continuous intra-arterial nimodipine treatment
significantly correlates with the outcome (GOS) (Spearman
𝑟 = −0.4070 (corrected for ties), 95% confidence interval:
−0.675 to−0.04351, two-tailed𝑃 value is 0.0256); see Figure 4.
Linear correlation of rCBF and ptiO2 before intra-
arterial nimodipine treatmentwas not significant (correlation
coefficient (𝑟) = −0.4147, 95% confidence interval: −0.7119
to 0.008456, Coefficient of determination (𝑟 squared) =
0.1720, two-tailed 𝑃 value is 0.0550). Correlating rCBF and
ptiO2 during intra-arterial nimodipine infusion, we get high
significance from 2 hours until day 4 with too little data on
day 5 to get valuable statistic information. We have picked
out “day one” to show correlation (correlation coefficient
(𝑟) = −0.7348, 95% confidence interval: −0.8829 to −0.4538,
coefficient of determination (𝑟 squared) = 0.5400, two-tailed
𝑃 value is <0.0001); see Figure 5.
Spearman rank test shows significant correlation for
ptiO2 before treatment (Spearman 𝑟 = 0.6667 (corrected
for ties), 95% confidence interval: 0.3290 to 0.8532, two-
tailed 𝑃 value is 0.0007) and during continuous intra-arterial
nimodipine therapy (Spearman 𝑟 = 0.8008 (corrected for
ties), 95% confidence interval: 0.5633 to 0.9160, two-tailed 𝑃
value is <0.0001) with GOS on discharge.


















Figure 3: Correlation of H&H grade and patient outcome. Spear-
man rank test shows inverted correlation of Hunt & Hess grade on
admission and outcome (GOS) on discharge.
Results of CT perfusion scanning are shown in Table 5.
One can see from the data that initial perfusion scanning
missed vasospasm only once and therefore seems to be a very
sensitive monitoring parameter.
4. Discussion
Continuous selective intra-arterial infusion of nimodipine
has been described before byMusahl et al. [20]. In contrast to
our results, none of their patients had “new ischemic lesions
caused by vasospasm” on discharge. This aspect is alarming,
as ischemia is one of the main reasons for neurologic deficit
in these patients. In our cohort, we had started continuous
intra-arterial nimodipine on day 9.19 ± 3.31 after SAH. On
average, Musahl started more than one day earlier: day 7.5 ±
2.06. Comparing these data, an important issue seems to be
the onset of treatment.
In our cohort from thirty patients, two had incidental
MCA bifurcation aneurysm and were treated with clipping.
One patient had clinical symptoms of confusion and speech
disturbance after awakening from surgery. CT perfusion
showed reduced perfusion frontotemporal but no area of
infarction. Symptoms disappeared within a few hours and,
as a result, no angiography was performed. Five days later,
motor and sensory speech deficits reoccurred. CT perfusion
and native cranial CT (CCT) showed infarction in themedian
territory frontotemporal. On angiography, vasospasm of a
distally from the clip localized MCA branch plus the anterior
cerebral artery, segment 1 (A1) left-sided, showed vasospasm.
After two days, symptoms improved and the catheter was
removed. Under logopedic therapy, the patient was able
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Figure 4: Correlation of onset of selective continuous intra-arterial
nimodipine infusion and patient outcome. Spearman rank test
shows that inverted correlation of the day nimodipine infusion was






















Figure 5: Linear correlation test shows extremely high significance
of ptiO2 and rCBF values during (day 1) selective continuous intra-
arterial nimodipine infusion.
other Hunt & Hess 0 case was admitted to our hospital
because of transitory ischemic attack (TIA) with dysarthria
and hemiparesis. On CT angiography, two aneurysms of
the right median bifurcation were identified. Transcranial
Doppler showed both-sided M1- and left-sided ICA stenosis
and a free ICA on the right with a history of thromboen-
darterectomy (TEA). Both aneurysms were clipped. After
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Table 5: Results of CT perfusion scanning before, during, and after treatment with continuous intra-arterial nimodipine infusion.
Case no. Before During After
Tissue at risk Infarction Tissue at risk Infarction Infarction
1 Yes Minor Yes Major Major
2 Yes No Yes Major Major
3 Yes No Yes Minor Minor
4 Yes No No No No
5 Yes No Yes No No
6 Yes No Yes Minor Major
7 Yes Minor Yes Minor Multiple minor
8 Yes Major Yes Major Major
9 Yes No Yes No Minor
10 Yes No Yes Minor Major
11 Yes No Yes No Minor
12 Yes No Yes Major Major
13 Yes No Yes Minor Major
14 Yes Minor Yes No Multiple minor
15 Yes No No No No
16 Yes No Yes No Minor
17 Yes No Yes Minor Multiple minor
18 Yes Minor Yes No Minor
19 Yes No Yes No Minor
20 Yes No Yes Minor Multiple minor
21 Yes Minor Yes No Multiple minor
22 Yes No Yes No Minor
23 Yes No Yes No Minor
24 Yes No Yes Minor Multiple minor
25 No No Yes No No
26 Yes No Yes No Minor
27 Yes No Yes No Minor
28 Yes No Yes Minor Minor
29 Yes Minor Yes Major Major
30 Yes No Yes Minor Minor (cerebellar)
anesthesia, epileptic seizures occurred. The perfusion scan
showed hyperperfusion of the right hemisphere, especially
parietooccipital. The patient did not wake up. CCT and CT
perfusion seven days after clipping illustrated a swollen right
hemisphere and hypodense brain tissue in the right-sided
median and posterior territories, suspect for infarctions.
After 3 days of continuous intra-arterial nimodipine infusion,
the vasospasm had disappeared, but infarction areas were
fixed and, with it, the patients symptoms on waking. On
discharge, a left-sided hemiparesis and psychomotor decel-
eration were noticed.
All of our patients showed persistent vasospasm after
30 minutes of intra-arterial infusion of 10mL nimodipine
solution in the angiography unit. Vasospasm improved in 26
patients after continuous intra-arterial nimodipine infusion.
Recurrence of vasospasmwas seen in 4 patients who received
the same treatment oncemore. A third cycle was only needed
once. All patients who neededmore than one treatment cycle
of continuous intra-arterial nimodipine infusionwere graded
Fisher 4 on initial CT scan.
It is remarkable that ptiO2 values showed such prompt
and extensive response. Value changes in other cases were
not as high as reported by Musahl et al. [20]. Hoelper
et al. [21] also have described the increase of ptiO2, but Stiefel
et al. [22] have found decreased tissue oxygenation during
endovascular vasospasm therapy.
Musahl et al. [20] describe the great effect on flow
velocities in transcranial Doppler after onset of intra-arterial
nimodipine treatment. In our study, we could not detect
reliable changes in flow velocities. In some cases we missed
clinical and angiographic improvement of vasospasm and in
others we did not detect beginning or manifest vasospasm.
A review by Lysakowski et al. [23] describes transcranial
Doppler as not decisive and so should not be used as the only
neuromonitoring parameter.
Our patients showed great response of rCBF-values on
intra-arterial nimodipine administration. The same effect
could be shown by Vajkoczy et al. [24], using intra-arterial
papaverine for antivasospastic therapy.
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In correlation with Moftakhar et al. [25] and Majoie
et al. [26] results we found good correlation of vasospasm
and findings in CT perfusion scanning. It marked tissue at
risk with prolonged time to peak and mean transit time
and showed a mismatch of cerebral blood flow and cerebral
blood volume with a sensitivity of 97% in our case series.
Native CAT scan missed many of these cases especially in
early stage of vasospasm. Some of our patients never showed
ischemic changes on native CT scan even if CT perfusion
detected tissue at risk areas for over a week with correlating
angiographic vasospasm.
Our protocol for continuous selective intra-arterial nimo-
dipine infusion is easily feasible. Infrastructural prerequisites
include angiography plus intensive or intermediate care unit.
The radiologist should be experienced in the interpretation
of intracranial digital subtraction angiography and be able
to intervene. A neurosurgeon should at least be on call if
major problems occur, which need to be treated surgically.
Most hospitals treating patients with SAH dispose of these
departments anyway. The equipment needed is a 4 or 5
French introducer sheath with a microcatheter + nimodipine
solution. Multimodal neuromonitoring is recommended.
Vessel wall dissection, catheter dislocation, and embolic
infarction due to thrombotic adhesion at catheter or vessel
wall are risks which should be kept in mind but have not
been reported so far. There were three suspect findings for
thrombotic vessel wall adhesions on CT angiography, but
none of these patients suffered embolic infarction. To prevent
embolic complications, anticoagulation is an important issue.
In our study, 10,000 IU/24 h heparin was infused via the same
catheter as nimodipine. Mayer et al. [27] and Musahl et al.
[20] used comparable protocols and did not notice serious
side effects or complications.
From thirty patients, one died of sepsis three days after
catheter removal. Even if the catheter tip was sterile on
microbiological tests, we cannot rule out correlation between
intra-arterial catheter and sepsis. But having in mind that
most of these patients were critically ill a sepsis rate of 3.3% is
within the normal range, even lower, than in other ICU series
[28].
None of the dead patients were autopsied. Therefore,
causes of death are clinical interpretations but cannot be
assured. One could say that this issue is a “black box.” We
could have missed death causing problems connected to the
catheter. Risk analysis for that is not purposeful.
We could not detect correlation between patient age and
onset of vasospasm, duration of intra-arterial nimodipine
application, or outcome. Results were the same for correlation
of sex and other parameters. Hunt & Hess did not predict
duration of therapy, but the Spearman rank correlation
test showed significant difference in outcome; see Figure 3.
The onset of continuous intra-arterial nimodipine treatment
significantly correlates with the outcome (GOS); see Figure 4.
Results in our study are worse than those reported by
Musahl et al. [20]. Comparing the patient population in
both studies, mean age is 47 years with Musahl et al. [20]
and 49.8 years in our study. The WFNS compared to the
Hunt & Hess score used in our study does not show a great
difference in the severity of cases included in both studies.
Two-thirds of Musahl et al. [20] patients were coiled on their
aneurysm whereas only 7% of our patients were coiled as the
only aneurysm treatment. One more aspect is the onset of
intra-arterial nimodipine treatment.Musahl et al. [20] started
one day earlier after bleeding and within 2 hours of onset
of symptoms, which presupposes an excellent infrastructure.
Patient age, aneurysm coiling, and time onset of treatment
seem to be important facts for better patient outcome. The
first cannot be influenced. The next two should be analyzed
in further studies.
We only included patients that did not respond to tripleH
therapy plus short-time intra-arterial infusion of nimodipine
in the angiography unit, which makes the patients included
in our study have more severe vasospasm from the start.
5. Conclusion
As selective continuous intra-arterial nimodipine infusion
seems to be a safe and easy therapy, one should think of
implementing it as soon as possible to prevent permanent
ischemia. Multimodal neuromonitoring seems to be helpful
in judging efficacy and safety of this new established treat-
ment. Further investigations could reveal certain criteria, in
which patients are likely to profit from continuous intra-
arterial nimodipine application and in whom a different
therapy should be started. Up till now, patient cohorts are
too small to give recommendations. This should change in
the near future.
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